Skip to content

Evaluation of the effect of Portulaca oleracea L. seed extract in patients with myocardial infarction

Evaluation of the effectiveness of Portulaca oleracea L. seed extract on the hs CRP level in patients with myocardial infarction

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220516054874N3
Enrollment
68
Registered
2022-07-17
Start date
2023-04-04
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: MI patients receiving Portulaca oleracea L. seed extract 300 mg twice daily for one month along with standard treatment. Intervention 2: Control group: MI patients

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with MI according to the American College of Heart criteria Consent to admission to the study Age more than 18 years old No kidney failure under hemodialysis No kidney failure and GFR<30 No thrombocytopenia No severe liver failure with liver enzymes three times more than normal No treatment with corticosteroids or immunosuppressive drugs No treatment with diltiazem or verapamil

Exclusion criteria

Exclusion criteria: Lack of consent to continue the study

Design outcomes

Primary

MeasureTime frame
Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.

Secondary

MeasureTime frame
Changes in CBC diff. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Interleukin-6 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vafa Baradaran Rahimi

Mashhad University of Medical Sciences

baradaranrv@mums.ac.ir0095 5138012739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026